CymaBay Therapeutics Inc (NASDAQ:CBAY) Expected to Post Earnings of -$0.39 Per Share

Equities analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to announce earnings of ($0.39) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.45). CymaBay Therapeutics reported earnings of ($0.32) per share in the same quarter last year, which suggests a negative year over year growth rate of 21.9%. The company is expected to issue its next earnings report on Thursday, February 27th.

On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($1.49) per share for the current fiscal year, with EPS estimates ranging from ($1.56) to ($1.42). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.59) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01).

CBAY has been the subject of several recent research reports. Zacks Investment Research upgraded CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Tuesday, January 7th. Roth Capital lowered CymaBay Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $22.00 to $2.00 in a research report on Tuesday, November 26th. HC Wainwright reiterated a “neutral” rating on shares of CymaBay Therapeutics in a research report on Friday, December 20th. Leerink Swann lowered CymaBay Therapeutics to a “hold” rating and set a $2.50 price target for the company. in a research report on Tuesday, November 26th. Finally, Oppenheimer lowered CymaBay Therapeutics from an “outperform” rating to a “hold” rating in a research report on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $6.56.

CBAY traded down $0.03 on Friday, hitting $1.90. The company had a trading volume of 862,868 shares, compared to its average volume of 1,094,210. The company has a market cap of $130.53 million, a PE ratio of -1.34 and a beta of 1.13. CymaBay Therapeutics has a 12-month low of $1.29 and a 12-month high of $14.00. The company has a quick ratio of 13.12, a current ratio of 13.12 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $4.49.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Montreal Can lifted its stake in CymaBay Therapeutics by 1,372.0% in the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,311 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in CymaBay Therapeutics in the second quarter worth about $80,000. Tower Research Capital LLC TRC bought a new stake in CymaBay Therapeutics in the third quarter worth about $61,000. SG Americas Securities LLC bought a new stake in CymaBay Therapeutics in the third quarter worth about $85,000. Finally, Diversified Trust Co bought a new stake in CymaBay Therapeutics in the fourth quarter worth about $38,000. 96.49% of the stock is owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.